Cns Pharmaceuticals, Inc. (CNSP) intrinsic value & 10-year financials
Cns Pharmaceuticals, Inc. (CNSP) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $4.85
- Market cap
- $2.2M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -1132.5%
- Free cash flow (FY2025)
- -$13.8M
CNSP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$15.9M | -$35.75 | -$13.8M | — | -298.8% |
| FY2024 | — | -$14.9M | -$38.87 | -$17.1M | — | -1708.5% |
| FY2023 | — | -$18.9M | -$5.00 | -$14.1M | — | -1019.5% |
| FY2022 | — | -$15.3M | -$11.22 | -$10.6M | — | -206.9% |
| FY2021 | — | -$14.0M | -$16.50 | -$13.5M | — | -3588.8% |
| FY2020 | — | -$9.5M | — | -$7.3M | — | -2418.9% |
| FY2019 | — | -$3.9M | — | -$3.6M | — | -108.7% |
| FY2018 | — | -$7.4M | — | -$716.4K | — | 290.1% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
CNS Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
CNS Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -24.8% ROIC.
CNS Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
CNS Pharmaceuticals, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.